These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21848883)

  • 21. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
    Chihara D; Cheah CY; Westin JR; Fayad LE; Rodriguez MA; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Cabanillas F; Kantarjian H; Kwak LW; Wang ML; Romaguera JE
    Br J Haematol; 2016 Jan; 172(1):80-8. PubMed ID: 26648336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
    Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P
    Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
    Oki Y; Westin JR; Vega F; Chuang H; Fowler N; Neelapu S; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale M; Younes A; Rodriguez MA; Orlowski RZ; Wang M; Ouzounian ST; Samaniego F; Fayad L
    Br J Haematol; 2013 Dec; 163(5):611-20. PubMed ID: 24117234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
    Fayad L; Thomas D; Romaguera J
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
    Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
    Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
    Gerecitano J; Portlock C; Hamlin P; Moskowitz CH; Noy A; Straus D; Schulman P; Dumitrescu O; Sarasohn D; Pappanicholaou J; Iasonos A; Zhang Z; Mo Q; Horanlli E; Rojas CN; Zelenetz AD; O'Connor OA
    Clin Cancer Res; 2011 Apr; 17(8):2493-501. PubMed ID: 21346146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of older patients with mantle-cell lymphoma.
    Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
    N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
    Lamm W; Kaufmann H; Raderer M; Hoffmann M; Chott A; Zielinski C; Drach J
    Haematologica; 2011 Jul; 96(7):1008-14. PubMed ID: 21486866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.
    Räty R; Honkanen T; Jantunen E; Jyrkkiö S; Karjalainen-Lindsberg ML; Kuittinen O; Lehto M; Mikkola M; Poikonen E; Rauhala A; Rimpiläinen J; Räsänen A; Siitonen S; Suominen M; Vapaatalo M; Elonen E
    Leuk Lymphoma; 2012 Oct; 53(10):1920-8. PubMed ID: 22397313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical analysis of 140 cases of mantle cell lymphoma].
    Hu MW; Lou YJ; Yang M; Wang HF; Wang L; Jin J
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):390-395. PubMed ID: 29860768
    [No Abstract]   [Full Text] [Related]  

  • 35. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
    Thomas DA; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Ravandi F; Verstovsek S; Jorgensen JL; Bueso-Ramos C; Andreeff M; Pierce S; Garris R; Keating MJ; Cortes J; Kantarjian HM
    J Clin Oncol; 2010 Aug; 28(24):3880-9. PubMed ID: 20660823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
    Howard OM; Gribben JG; Neuberg DS; Grossbard M; Poor C; Janicek MJ; Shipp MA
    J Clin Oncol; 2002 Mar; 20(5):1288-94. PubMed ID: 11870171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
    Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
    Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
    Damon LE; Johnson JL; Niedzwiecki D; Cheson BD; Hurd DD; Bartlett NL; Lacasce AS; Blum KA; Byrd JC; Kelly M; Stock W; Linker CA; Canellos GP
    J Clin Oncol; 2009 Dec; 27(36):6101-8. PubMed ID: 19917845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
    Press OW; Unger JM; Rimsza LM; Friedberg JW; LeBlanc M; Czuczman MS; Kaminski M; Braziel RM; Spier C; Gopal AK; Maloney DG; Cheson BD; Dakhil SR; Miller TP; Fisher RI
    J Clin Oncol; 2013 Jan; 31(3):314-20. PubMed ID: 23233710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results.
    Alderuccio JP; Saul EE; Iyer SG; Reis IM; Alencar AJ; Rosenblatt JD; Lossos IS
    Am J Hematol; 2021 Jun; 96(6):680-689. PubMed ID: 33735476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.